COVID-19
Inhibitory Selectivity
COVID-19 Products
| Catalog No. | Information | Product Use Citations | Product Validations |
|---|---|---|---|
| S2926 |
TDZD-8TDZD-8 (NP 01139) is a non-ATP competitive GSK-3β inhibitor with IC50 of 2 μM; minimal inhibitory effect observed on CDK1, casein kinase II, PKA and PKC. |
The impact of GSK3β inhibitor TDZD-8 (10 μM) on the GSK3β phosphorylation (A), the protein expression (B) and mRNA level (C) of α-SMA and collagen I in acetaldehyde-induced HSCs activation. The data were representative of at least three independent experiments. All values were expressed as mean ± SD. *P < 0.01, ***P < 0.01 vs. the control group, #P < 0.05, ##P < 0.01, ###P < 0.01 vs. the acetaldehyde group.
|
|
| S9866New |
Nirmatrelvir (PF-07321332)Nirmatrelvir (PF-07321332) is an reversible covalent inhibitor of SARS-CoV-2 main protease (Mpro, also referred to as 3CL protease) with an ki of 3.11 nM. PF-07321332 binds directly to the catalytic cysteine (Cys145) residue of the enzyme. |
||
| S8279 |
Shikonin (C.I. 75535)Shikonin (C.I. 75535, Anchusin, Anchusa acid, Alkanna Red, Isoarnebin 4, NSC 252844), a potent and specific Pyruvate kinase M2 (PKM2) inhibitor, is a major component of zicao (purple gromwell, the dried root of Lithospermum erythrorhizon), a Chinese herbal medicine with various biological activities. It is also an inhibitor of TMEM16A chloride channel activity using cell-based fluorescent-quenching assay. Shikonin exerts an anti-inflammatory effect by inhibiting tumor necrosis factor-α (TNF-α) and prevents activation of nuclear factor-κB (NF-κB) pathway via proteasome inhibition. |
||
| S0833 |
EIDD-1931EIDD-1931 (Beta-d-N4-hydroxycytidine, β-d-N4-hydroxycytidine, NHC) is an active metabolite of EIDD-2801, a promising COVID-19 inhibitor. EIDD-1931 (NHC) has broad spectrum antiviral activity against SARS-CoV-2, MERS-CoV, SARS-CoV, and related zoonotic group 2b or 2c Bat-CoVs with average IC50 of 0.15 μM, as well as increased potency against a coronavirus bearing resistance mutations to the nucleoside analog inhibitor remdesivir. |
||
| S9858New |
Lufotrelvir (PF-07304814)PF-07304814 is a phosphate prodrug of PF-00835231 that binds and inhibits SARS-CoV-2 3CLpro activity with a Ki of 174 nM. |
||
| E1174New |
NK01-63NK01-63 (Coronastat) is a potent inhibitor of the SARS-CoV-2 3CL protease, which is a critical drug target for small molecule COVID-19, given its likely druggability and essentiality in the viral maturation and replication cycle. |
||
| E1131New |
S-217622S-217622 (Ensitrelvir fumarate) is the first orally active non-covalent, non-peptidic, SARS-CoV-2 3CL protease inhibitor with IC50 of 13 nM. |
||
| S9963New |
paquinimodPaquinimod (ABR 25757), a specific inhibitor of S100A8/A9, could rescue the pneumonia with substantial reduction of viral loads in SARS-CoV-2-infected mice. |
||
| E1111New |
VV116VV116, a promising orally administered anti-SARS-CoV-2 nucleoside drug candidate, exerts functions by targeting the viral RNA-dependent RNA polymerase through its nucleoside triphosphate form with an IC50 of 0.67±0.24 μM. |
||
| E1112New |
GS-621763GS-621763, an orally bioavailable prodrug of GS-441524, shows a dose-dependent antiviral effect on SARS-CoV-2 reporter virus expressing nanoluciferase (SARS-CoV-2 nLUC) replication with an EC50 of 2.8 μM, also inhibits reporter SARS-CoV-2 expressing firefly luciferase (SARS-CoV-2 Fluc) replication with EC50 of 0.125 μM. |
||
| S3511 |
FOY251FOY251, an active metabolite of camostat mesilate, is an inhibitor of synthetic serine protease. FOY251 inhibits SARS-CoV-2 infection. |
||
| S6676 |
EbselenEbselen (DR 3305, SPI-1005, PZ-51, CCG-39161) is a small-molecule capsid inhibitor of HIV-1 Replication with IC50 of 46.1 nM in TR-FRET assay. |
||
| S8969 |
Molnupiravir (EIDD-2801)Molnupiravir (EIDD-2801, MK-4482) is an orally bioavailable prodrug of the ribonucleoside analog β-d-N4-hydroxycytidine (NHC; EIDD-1931) with broad-spectrum antiviral activity against SARS-CoV-2, MERS-CoV, SARS-CoV, and the causative agent of COVID-19. |
||
| S6999 |
Chloroquine (NSC-187208)Chloroquine (NSC-187208, Aralen, CHQ, CQ) is an antimalarial drug and autophagy/lysosome inhibitor. Chloroquine also suppresses Toll-like receptor-9 (TLR9) protein expression. Chloroquine is highly effective agianst SARS-CoV-2 (COVID-19) infection with EC50 of 1.13 μM in Vero E6 cells. Chloroquine has anti-HIV-1 activity. |
||
| S0875 |
XP-59XP-59 is a potent inhibitor of the SARS-CoV Mpro, with a Ki of 0.1 μM. |
||
| E0052 |
MerafloxacinMerafloxacin (CI-934) is a fluoroquinolone antibacterial thats inhibit -1 frameshifting efficiency of SARS-CoV-2 and other betacoronaviruses. |
||
| S9731 |
PF-00835231PF-00835231 is a 3CLpro (Mpro) inhibitor that may targets SARS-CoV-2 protease 3CLpro as a potential new treatment for COVID-19. |
||
| S8932 |
Remdesivir (GS-5734)Remdesivir (GS-5734), a monophosphoramidate prodrug of an adenosine analog, is an investigational broad-spectrum antiviral agent with in vitro activity against multiple RNA viruses, including Ebola and CoV. |
||
| S3553 |
RiamilovirRiamilovir (Triazavirin) is a broad-spectrum antiviral drug candidate, which can be used for potential application against the Coronavirus 2019-nCoV. |
| Catalog No. | Information | Product Use Citations | Product Validations |
|---|---|---|---|
| S2926 |
TDZD-8TDZD-8 (NP 01139) is a non-ATP competitive GSK-3β inhibitor with IC50 of 2 μM; minimal inhibitory effect observed on CDK1, casein kinase II, PKA and PKC. |
The impact of GSK3β inhibitor TDZD-8 (10 μM) on the GSK3β phosphorylation (A), the protein expression (B) and mRNA level (C) of α-SMA and collagen I in acetaldehyde-induced HSCs activation. The data were representative of at least three independent experiments. All values were expressed as mean ± SD. *P < 0.01, ***P < 0.01 vs. the control group, #P < 0.05, ##P < 0.01, ###P < 0.01 vs. the acetaldehyde group.
|
|
| S9866New |
Nirmatrelvir (PF-07321332)Nirmatrelvir (PF-07321332) is an reversible covalent inhibitor of SARS-CoV-2 main protease (Mpro, also referred to as 3CL protease) with an ki of 3.11 nM. PF-07321332 binds directly to the catalytic cysteine (Cys145) residue of the enzyme. |
||
| S8279 |
Shikonin (C.I. 75535)Shikonin (C.I. 75535, Anchusin, Anchusa acid, Alkanna Red, Isoarnebin 4, NSC 252844), a potent and specific Pyruvate kinase M2 (PKM2) inhibitor, is a major component of zicao (purple gromwell, the dried root of Lithospermum erythrorhizon), a Chinese herbal medicine with various biological activities. It is also an inhibitor of TMEM16A chloride channel activity using cell-based fluorescent-quenching assay. Shikonin exerts an anti-inflammatory effect by inhibiting tumor necrosis factor-α (TNF-α) and prevents activation of nuclear factor-κB (NF-κB) pathway via proteasome inhibition. |
||
| S0833 |
EIDD-1931EIDD-1931 (Beta-d-N4-hydroxycytidine, β-d-N4-hydroxycytidine, NHC) is an active metabolite of EIDD-2801, a promising COVID-19 inhibitor. EIDD-1931 (NHC) has broad spectrum antiviral activity against SARS-CoV-2, MERS-CoV, SARS-CoV, and related zoonotic group 2b or 2c Bat-CoVs with average IC50 of 0.15 μM, as well as increased potency against a coronavirus bearing resistance mutations to the nucleoside analog inhibitor remdesivir. |
||
| S9858New |
Lufotrelvir (PF-07304814)PF-07304814 is a phosphate prodrug of PF-00835231 that binds and inhibits SARS-CoV-2 3CLpro activity with a Ki of 174 nM. |
||
| E1174New |
NK01-63NK01-63 (Coronastat) is a potent inhibitor of the SARS-CoV-2 3CL protease, which is a critical drug target for small molecule COVID-19, given its likely druggability and essentiality in the viral maturation and replication cycle. |
||
| E1131New |
S-217622S-217622 (Ensitrelvir fumarate) is the first orally active non-covalent, non-peptidic, SARS-CoV-2 3CL protease inhibitor with IC50 of 13 nM. |
||
| S9963New |
paquinimodPaquinimod (ABR 25757), a specific inhibitor of S100A8/A9, could rescue the pneumonia with substantial reduction of viral loads in SARS-CoV-2-infected mice. |
||
| E1111New |
VV116VV116, a promising orally administered anti-SARS-CoV-2 nucleoside drug candidate, exerts functions by targeting the viral RNA-dependent RNA polymerase through its nucleoside triphosphate form with an IC50 of 0.67±0.24 μM. |
||
| E1112New |
GS-621763GS-621763, an orally bioavailable prodrug of GS-441524, shows a dose-dependent antiviral effect on SARS-CoV-2 reporter virus expressing nanoluciferase (SARS-CoV-2 nLUC) replication with an EC50 of 2.8 μM, also inhibits reporter SARS-CoV-2 expressing firefly luciferase (SARS-CoV-2 Fluc) replication with EC50 of 0.125 μM. |
||
| S3511 |
FOY251FOY251, an active metabolite of camostat mesilate, is an inhibitor of synthetic serine protease. FOY251 inhibits SARS-CoV-2 infection. |
||
| S6676 |
EbselenEbselen (DR 3305, SPI-1005, PZ-51, CCG-39161) is a small-molecule capsid inhibitor of HIV-1 Replication with IC50 of 46.1 nM in TR-FRET assay. |
||
| S8969 |
Molnupiravir (EIDD-2801)Molnupiravir (EIDD-2801, MK-4482) is an orally bioavailable prodrug of the ribonucleoside analog β-d-N4-hydroxycytidine (NHC; EIDD-1931) with broad-spectrum antiviral activity against SARS-CoV-2, MERS-CoV, SARS-CoV, and the causative agent of COVID-19. |
||
| S6999 |
Chloroquine (NSC-187208)Chloroquine (NSC-187208, Aralen, CHQ, CQ) is an antimalarial drug and autophagy/lysosome inhibitor. Chloroquine also suppresses Toll-like receptor-9 (TLR9) protein expression. Chloroquine is highly effective agianst SARS-CoV-2 (COVID-19) infection with EC50 of 1.13 μM in Vero E6 cells. Chloroquine has anti-HIV-1 activity. |
||
| S0875 |
XP-59XP-59 is a potent inhibitor of the SARS-CoV Mpro, with a Ki of 0.1 μM. |
||
| E0052 |
MerafloxacinMerafloxacin (CI-934) is a fluoroquinolone antibacterial thats inhibit -1 frameshifting efficiency of SARS-CoV-2 and other betacoronaviruses. |
||
| S9731 |
PF-00835231PF-00835231 is a 3CLpro (Mpro) inhibitor that may targets SARS-CoV-2 protease 3CLpro as a potential new treatment for COVID-19. |
||
| S8932 |
Remdesivir (GS-5734)Remdesivir (GS-5734), a monophosphoramidate prodrug of an adenosine analog, is an investigational broad-spectrum antiviral agent with in vitro activity against multiple RNA viruses, including Ebola and CoV. |
| Catalog No. | Information | Product Use Citations | Product Validations |
|---|---|---|---|
| S3553 |
RiamilovirRiamilovir (Triazavirin) is a broad-spectrum antiviral drug candidate, which can be used for potential application against the Coronavirus 2019-nCoV. |
